Specific inhibition of the subunits of ribonucleotide reductase as a new approach to combination chemotherapy.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002286:Carcinoma, Ehrlich Tumor / Q000201:enzymology; D004347:Drug Interactions; D004357:Drug Synergism; D005260:Female; D006144:Guanazole / Q000494:pharmacology; D006918:Hydroxyurea / Q000494:pharmacology; D007502:Iron Chelating Agents / Q000494:pharmacology; D007546:Isoquinolines / Q000494:pharmacology; D051379:Mice; D011720:Pyrazoles / Q000494:pharmacology; D012262:Ribonucleoside Diphosphate Reductase / Q000037:antagonists & inhibitors*; D012264:Ribonucleotide Reductases / Q000037:antagonists & inhibitors*; D013882:Thiosemicarbazones / Q000494:pharmacology
D000970:Antineoplastic Agents; D007502:Iron Chelating Agents; D007546:Isoquinolines; D011720:Pyrazoles; D013882:Thiosemicarbazones; C002526:1-formylisoquinoline thiosemicarbazone; C013118:4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone; D012264:Ribonucleotide Reductases; D012262:Ribonucleoside Diphosphate Reductase; D006144:Guanazole; C000971:2,3-dihydro-1H-imidazo(1,2-b)pyrazole; D006918:Hydroxyurea